ストックスクリーナーアプリを入手
70.41
1.95%
-1.40
前日終値:
$71.81
開ける：
$71.88
24時間の取引高:
984.37K
Relative Volume:
0.83
時価総額：
$7.19B
収益：
$1.64B
当期純損益:
$121.85M
株価収益率:
45.72
EPS:
1.54
ネットキャッシュフロー:
$-480.40M
1週間 パフォーマンス:
-4.98%
1か月 パフォーマンス:
-31.68%
6か月 パフォーマンス:
-43.46%
1年 パフォーマンス:
-45.61%
1日の値動き範囲:
$69.81
$72.05
1週間の範囲:
$69.81
$76.67
52週間の値動き範囲:
$69.81
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
SRPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
70.41 | 7.19B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? - MSN
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates - Genetic Engineering & Biotechnology News
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Safety Questions Loom in Duchenne as Dyne, Wave and Others Plan FDA Filings - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Wave strengthens case for accelerated approval, with more positive Duchenne data - Endpoints News
Sarepta stock plunges to 52-week low, touches $73 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Markets Insider
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion - Yahoo Finance
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Is This Stock a Buy After a Massive 20% Drop in 1 Day? - Yahoo Finance
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta - Genetic Engineering & Biotechnology News
PNC Financial Services Group Inc. Has $352,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Scotiabank Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up - NewsBreak: Local News & Alerts
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors UK
This Is What Whales Are Betting On Sarepta Therapeutics - Benzinga
Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - News & Insights
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Givi - Asianet Newsable
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade - Defense World
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price - Defense World
Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT) - Defense World
Sarepta plunges after death linked to Elevidys (update) - MSN
Sarepta: Should Investors Run For The Exit? (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics’ stock falls after patient dies of liver failure - MSN
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - Markets Insider
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades - PharmaVoice
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On - BioSpace
Sarepta Therapeutics (NASDAQ:SRPT) Given New $99.00 Price Target at Deutsche Bank Aktiengesellschaft - Armenian Reporter
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? - Yahoo Finance
Pulse of the Market: Wednesday’s 10 Top Performers - Insider Monkey
Medical Stocks To Follow Today – March 18th - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday? - Yahoo Finance
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion - MSN
Sarepta’s gene therapy faced internal FDA doubts. Now, a teen has died - Healthcare Brew
Sarepta reports death of DMD patient given gene therapy, Elevidys - Muscular Dystrophy News
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT) - Markets Insider
Sarepta Therapeutics’ SWOT analysis: strong Elevidys sales offset safety concerns - Investing.com
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies - MSN
Sarepta's gene therapy under scrutiny after patient death - Medical Xpress
UBS maintains Sarepta stock Buy rating, $188 target despite concerns - Investing.com
UBS maintains Sarepta stock Buy rating, $188 target despite concerns By Investing.com - Investing.com UK
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
Sarepta Therapeutics Inc (SRPT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):